ConforMIS, Inc. (CFMS) Shares Bought by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its position in ConforMIS, Inc. (NASDAQ:CFMS) by 2.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,021 shares of the medical instruments supplier’s stock after purchasing an additional 1,091 shares during the period. Wells Fargo & Company MN owned about 0.13% of ConforMIS worth $236,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. American International Group Inc. lifted its stake in ConforMIS by 7.0% in the first quarter. American International Group Inc. now owns 22,009 shares of the medical instruments supplier’s stock valued at $115,000 after purchasing an additional 1,448 shares during the last quarter. Trent Capital Management Inc. NC purchased a new position in ConforMIS in the second quarter valued at approximately $136,000. Rhumbline Advisers lifted its stake in ConforMIS by 21.8% in the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock valued at $192,000 after purchasing an additional 8,017 shares during the last quarter. Swiss National Bank lifted its stake in ConforMIS by 59.2% in the second quarter. Swiss National Bank now owns 53,500 shares of the medical instruments supplier’s stock valued at $230,000 after purchasing an additional 19,900 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in ConforMIS in the second quarter valued at approximately $430,000. Institutional investors and hedge funds own 36.41% of the company’s stock.

WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/11/21/conformis-inc-cfms-shares-bought-by-wells-fargo-company-mn.html.

CFMS has been the topic of several research analyst reports. Deutsche Bank AG reiterated a “hold” rating and issued a $5.00 price objective (down previously from $6.00) on shares of ConforMIS in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. set a $6.00 price objective on ConforMIS and gave the company a “buy” rating in a research note on Friday, August 4th. Canaccord Genuity lowered their target price on shares of ConforMIS from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Friday, August 4th. ValuEngine raised shares of ConforMIS from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Zacks Investment Research cut shares of ConforMIS from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $5.85.

Shares of ConforMIS, Inc. (CFMS) opened at $3.20 on Tuesday. The company has a quick ratio of 5.38, a current ratio of 6.19 and a debt-to-equity ratio of 0.52. ConforMIS, Inc. has a 1-year low of $3.03 and a 1-year high of $9.47.

ConforMIS (NASDAQ:CFMS) last issued its earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 76.88%. The business had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.55 million. During the same quarter in the previous year, the firm posted ($0.31) EPS. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. analysts expect that ConforMIS, Inc. will post -1.27 earnings per share for the current year.

In other ConforMIS news, CTO Daniel Steines sold 15,485 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $3.15, for a total transaction of $48,777.75. Following the sale, the chief technology officer now owns 254,652 shares of the company’s stock, valued at approximately $802,153.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Paul S. Weiner sold 17,723 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $3.17, for a total transaction of $56,181.91. Following the sale, the chief financial officer now directly owns 162,009 shares in the company, valued at approximately $513,568.53. The disclosure for this sale can be found here. Insiders have sold a total of 52,346 shares of company stock worth $166,598 in the last three months. Insiders own 9.55% of the company’s stock.

ConforMIS Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Institutional Ownership by Quarter for ConforMIS (NASDAQ:CFMS)

What are top analysts saying about ConforMIS Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ConforMIS Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit